Plain-English translation of NCT04883255 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers want to understand how cannabis affects thinking and brain chemistry in people with HIV. This trial will give participants either THC (the main active ingredient in cannabis), CBD (another cannabis compound), or a placebo for 5 days, then measure changes in decision-making, focus, and brain chemical levels to see if the medication has different effects in people with HIV versus without it.
Many people with HIV use cannabis to help with nausea, pain, and mood, but doctors don't yet know whether this treatment is truly safe or helpful—or how it might interact with HIV medications. This study will help answer those important questions.
You likely qualify if…
You likely don't qualify if…
You will first come in for baseline testing where you'll answer questions about your health and cannabis use, take cognitive tests (like decision-making exercises), and provide a blood sample to measure brain chemicals. Then you'll take the study medication (THC, CBD, or placebo) daily for 5 days at home. Finally, you'll return for follow-up testing that mirrors the baseline visit to see how the medication affected your thinking and brain chemistry.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
United States